Colorectal Cancer
Conditions
Brief summary
Evaluation of CG-100 Intraluminal Bypass device
Interventions
Subjects will be treated with the CG-100 Intraluminal Bypass Device
Sponsors
Colospan Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
22 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
(pre-operative): 1. Willing to comply with protocol-specified follow-up evaluations 2. 22-75 (inclusive) years of age at screening 3. Diagnosed with colorectal cancer 4. Has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety of the CG-100 Intraluminal Bypass Device | 10 days | Assessment of Serious Adverse Events |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety of the CG-100 Intraluminal Bypass Device | 4 weeks | Assessment of Serious Adverse Events |
Countries
Israel
Outcome results
None listed